65,437 trials
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Parathyroid Hormone
Primary: Percentage of Subjects Achieving at Least a 40% Reduction of iPTH (Intact Parathyroid Hormone) From Baseline — 58.1 percentage of participants
Influenza
Primary: CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection — 2.24; 3.87 Ratio
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
HIV-1 Patients
Primary: CD4 Count — 229.9; 208.8; 246.8 cells per mm³
Sarcoma
Primary: Number of Patients With Sarcoma Who Are Tumor Progression Free and Alive at Four Months From Start of Treatment With Single-agent Cetuximab. — 3; 1 participants — p=<0.05
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
Chronic Idiopathic Urticaria
Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) During the Treatment Period (up to 5.5 Years) — 311 Subjects
Coronary Artery Disease
Primary: The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition…
Tobacco Dependence
Primary: 7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8) — 7; 5; 7 participants — p=0.615
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Dose Schedule Study
Primary: Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule. — 0.93; 0.99; 0.63; 1.0 GMT ratio
Lymphoma, Large-Cell, Diffuse
Primary: Number of Participants With Objective Response — 9 participants
Epilepsy
Primary: Seizure Reduction Rate — -16.35 Percentage of Seizure Reduction Rate